Drugs / Trifluridine/tipiracil hydrochloride
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03869892 | Mar 2019 → Jun 2021 overdue | colorectal cancer | Servier | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/tipiracil hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03869892 ↗ |
| Known as | S95005 | “Trifluridine/tipiracil hydrochloride (S95005)” NCT03869892 ↗ |
| Route | Oral | “Film-coated tablets of S 95005 (35 mg/m²/dose) will be administered orally” NCT03869892 ↗ |